
ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
Date of Release: July 28, 2022
Expiration Date: July 31, 2024
Credits offered: CME
Estimate time of completion: 1 hour
Course must be completed by the expiration date
Course Description
In this session, Dr. Park will be discussing several cases brought to our Vanderbilt-Ingram Cancer Center Hereditary and Oncologic Personalized Evaluation (VICC HOPE) Molecular Tumor Board to highlight how tumor/germline next-generation sequencing (NGS), along with liquid biopsies using circulating tumor DNA (ctDNA), can result in actionable findings for patients with cancer. These cases will emphasize differences in germline findings that may or may not affect clinical decision making, as well as highlight newer technologies of RNA NGS for both tumor and germline testing, that can also lead to clinical utility.
Target Audience
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
Learning Objectives
At the conclusion of this session, participants should be able to:
1. Describe the difference between somatic testing with germline filtering and true germline testing
2. Demonstrate the application of RNA for tumor testing and germline testing
3. Discuss the importance of molecular tumor boards for correct interpretation of results for on label and off label use of cancer therapies